Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study
European Journal of Medical Research · 2025
DOI: 10.1186/s40001-025-02406-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Medical Research, 2025. Verfasst von Bangbei Wan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medical Center, Hainan Women and Children's Medical Center, Haikou, China. 939313612@qq.com. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Urinary Bladder, Overactive, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research and Cultivation Fund of Hainan Medical University, Hainan Province Clinical Medical Center, Natural Science Foundation of Hainan Province.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Overactive bladder (OAB) syndrome has a significant impact on quality of life, and vibegron has emerged as a therapeutic option. This study aims to evaluate the safety profile of vibegron in a disproportionality analysis by analyzing adverse event (AE) reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Methods
We conducted a retrospective analysis of the FAERS database from January 2021 to September 2023. After duplicate removal and thorough screening, 1137 vibegron-related AE reports were identified. We analyzed these reports for demographic and clinical characteristics, signal detection at the system organ class (SOC) level, and specific AEs.
Results
Females comprised a higher percentage (67.72%) of AE reports compared to males. The elderly population (age > 64 years) accounted for 15.84% of the cases. The majority (95.69%) of the reports originated from the USA. Signal detection revealed significant findings across 19 organ systems with notable SOCs, including renal and urinary disorders (ROR = 7.72, 95%CI 6.83–8.72), gastrointestinal disorders (ROR = 1.38, 95%CI 1.21–1.58), and respiratory, thoracic, and mediastinal disorders (ROR = 1.21, 95%CI 1.01–1.45). In addition, several unexpected AEs were identified, such as dry mouth, hot flush, constipation, and increased blood pressure.
Conclusions
This study provides comprehensive insights into vibegron's safety profile, revealing both known and unexpected AEs. The findings highlight the need for careful patient selection and monitoring, especially among females and the elderly. The results advocate for ongoing pharmacovigilance and further research to ensure vibegron's safe and effective use in OAB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reproductive Medical Center, Hainan Women and Children's Medical Center, Haikou, China. 939313612@qq.com.
- Department of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China. 939313612@qq.com.
- Reproductive Medical Center, Hainan Women and Children's Medical Center, Haikou, China.
- Reproductive Medical Center, Hainan Women and Children's Medical Center, Haikou, China. hn121018021@163.com.
Förderung
- Research and Cultivation Fund of Hainan Medical University
- Hainan Province Clinical Medical Center
- Natural Science Foundation of Hainan Province
- Key R&D Projects of Hainan Province
- Specific Research Fund of The Innovation Platform for Academicians of Hainan Province
Zitieren
APA
Wan, B., Zhou, Z., Ma, N., & Lu, W. (2025). Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study. European Journal of Medical Research. https://doi.org/10.1186/s40001-025-02406-9
Vancouver
Wan B, Zhou Z, Ma N, Lu W. Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study. European Journal of Medical Research. 2025. doi:10.1186/s40001-025-02406-9
BibTeX
@article{Wan2025,
author = {Wan, Bangbei and Zhou, Zhi and Ma, Ning and Lu, Weiying},
title = {Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study},
journal = {European Journal of Medical Research},
year = {2025},
doi = {10.1186/s40001-025-02406-9}
}
EUVIMED